Baseline Sleep Apnea Study #2

Overview

This is a single group, unblinded, prospective clinical study. This study seeks to understand patient diagnostic and treatment journey and positive airway pressure (PAP) therapy compliance for Verily Sleep Apnea (VSA) program/app users. Participants will enroll remotely and may undergo a home sleep test (HST). Upon confirmation of obstructive sleep apnea (OSA) and prescription of PAP therapy, the participant will begin using the VSA app to supplement PAP treatment. After 90 days of active participation, the participant will be given instructions for follow-up care, as indicated.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 30, 2021

Interventions

  • Device: Verily Sleep Apnea (VSA) Program/App
    • The VSA program/app, is an Obstructive Sleep Apnea (OSA) management platform.

Arms, Groups and Cohorts

  • Experimental: Arm 1
    • Participants told they may have Obstructive Sleep Apnea (OSA) and provided a home sleep test (HST)

Clinical Trial Outcome Measures

Primary Measures

  • Time (Number of Days) From When Participant is Told They May Have OSA to When They Receive HST Prescription
    • Time Frame: 147 Days
    • Time (number of days) from when participant is told they may have OSA to when they receive HST prescription
  • Time (Number of Days) From When Participant Receives HST Prescription to When They Receive Their Diagnosis
    • Time Frame: 164 days
    • Time from when the participant receives HST prescription to OSA diagnosis.
  • Time (Number of Days) From OSA Diagnosis to PAP Therapy Initiation
    • Time Frame: 153 Days
    • Time from OSA diagnosis to PAP therapy initiation.
  • Time (Number of Days) From Therapy Initiation to When 90-day Compliance Threshold is Achieved
    • Time Frame: 90 Days
    • Time (number of days) from therapy initiation to when 90-day compliance threshold is achieved. 90-day Compliance is defined as ≥ 4 hours per night on 70% of nights during a consecutive 30 day period anytime during the first 90 days.

Secondary Measures

  • Completion Rates Among Individuals Who Had an HST Ordered
    • Time Frame: 161 Days
    • Among individuals prescribed a HST, % of individuals who completed the HST and had interpretable results.
  • Completion Rates Among Individuals Prescribed a PAP Device
    • Time Frame: 153 Days
    • Among individuals prescribed a PAP device, % of individuals who filled the order (PAP device delivered to them).
  • Completion Rates Among Individuals Prescribed a PAP Device
    • Time Frame: 90 Days
    • Percentage of individuals who used the PAP device at least once during the 90 days
  • Percent of Participants Who Meet 90 Day Compliance Success Criteria
    • Time Frame: 90 Days
    • Compliance Metrics – Percent of participants who meet 90 day compliance success criteria, as defined by: ≥ 4 hours per night on 70% of nights during a consecutive 30 day period anytime during the first 90 days

Participating in This Clinical Trial

Inclusion Criteria

  • Ages 18 or older – Able to speak and read English – Legal United States Resident with a Government Issued ID – Participating in the Project Baseline Community Study – Demonstrates understanding of the study requirements and is able and willing to sign the informed consent form – Own a smartphone with a data plan and be the primary user of the smartphone; smartphone must use Android Lollipop (5.1+/ API 22+) or iOS 11.X+ – Own a computer with a web camera – Consistent access to electricity and wifi for the duration of the study – Have a high risk of OSA as determined by screening questionnaire – Good candidate for PAP therapy, in the opinion of the managing clinician – Without significant limitation in ability to participate in the study, in the opinion of the investigator. Exclusion Criteria:

  • Previously diagnosed with sleep apnea or other sleep disorders, that in the opinion of the investigator, makes the participant ineligible (e.g., Obstructive Sleep Apnea, Central Sleep Apnea, Complex Sleep Apnea, chronic insomnia) – Participant is a shift worker (indicated by having a night shift schedule on a regular basis, or a work shift that changes or rotates on a daily, weekly, or monthly basis) – Sponsor employees and individuals working on Project Baseline – Self reported to be pregnant or planning to become pregnant during the study period – Current use of home oxygenation devices, such as supplemental oxygen

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Verily Life Sciences LLC
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Shannon Sullivan, MD, Principal Investigator, Verily Life Sciences LLC

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.